

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-16. (canceled).

17. (currently amended) A method of treating ~~inflammatory bowel disease or Crohn's Disease~~, which comprises administering to a patient having Crohn's Disease from about 800 mg to about 1,200 mg per day a therapeutically effective amount of enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound inhibits PDE4.

18-23. (canceled).

24. (previously presented) The method of claim 17 further comprising administering to the patient a therapeutically effective amount of anti-inflammatory drug, non-steroid anti-inflammatory drug, steroid, hematopoietic growth factor, cytokine, stem cell transplantation, or kinase inhibitor.

25-26. (canceled).

27. (previously presented) The method of claim 17 wherein the patient is a mammal.

28. (previously presented) The method of claim 17 wherein the enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, topically, or orally.

29. (currently amended) The method of claim 17 wherein ~~the therapeutically effective amount is from about 1 mg to about 5,000 mg per day~~ the compound is

administered in an amount of about 800 mg per day for 12 weeks and then the amount of the compound administered is increased to a maximum dose of about 1,200 mg per day for 12 weeks.

30-31. (canceled).

32. (previously presented) The method of claim 29, wherein the enantiomerically pure (-)-3-(3,4-dimethoxyphenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered twice a day.

33-46. (canceled).

47. (previously presented) The method of claim 17, wherein the patient is a human.